New drug combo JSKN033 tested for Hard-to-Treat cancers
NCT ID NCT06226766
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called JSKN033 in 11 people with advanced or spreading solid tumors that have a protein called HER2. The drug is a combination of two medicines given as a shot under the skin. The study aimed to check safety, side effects, and the right dose, but it was stopped early. It is too soon to know if this approach works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JSKN033 (a combination of two drugs: JSKN003 and envafolimab)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have a specific marker (HER2).
- What could go wrong
- This trial was terminated early and only enrolled 11 people, so results are very limited. It is a first-in-human study, meaning safety and effectiveness are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scientia Clinical Research
Randwick, New South Wales, 2031, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?